Celcuity Stock Jumps 16% as Gedatolisib Breast-Cancer Data Raise FDA Stakes
Celcuity Inc. shares rose nearly 16% Monday after reporting its breast cancer drug gedatolisib met the main goal in a late-stage trial for patients with PIK3CA-mutant tumors. The company plans to submit the new data to the FDA as a supplemental application. Celcuity traded at $145.54, up $19.89, with a market value near $6.9 billion. A July 17 FDA decision on gedatolisib for a related use remains pending.
